Antisense therapy targeting apolipoprotein(a): a randomised, double-blind, placebo-controlled phase 1 study - Tsimikas, Sotirios, Prof; Viney, Nicholas J, BSc; Hughes, Steven G, MBBS; Singleton, Walter, MD; Graham, Mark J, MS; Baker, Brenda F, PhD; Burkey, Jennifer L, PhD; Yang, Qingqing, MS; Marcovina, Santica M, Prof; Geary, Richard S, PhD; Crooke, Rosanne M, PhD; Witztum, Joseph L, Prof (The Lancet (British edition), 2015)
Keywords: Adolescent; Adult; Aged; Apolipoproteins; Apolipoproteins A - administration & dosage; Apolipoproteins A - genetics; Apoprotein(a) - antagonists & inhibitors; Atherosclerosis; Cardiovascular disease; Cardiovascular diseases; Cholesterol; Double-Blind Method; Drug therapy; Drugs; Health risks; Healthy Volunteers; Humans; Injection; Internal Medicine; Low density lipoprotein; Middle Aged; Oligonucleotides - administration & dosage; Oligonucleotides - pharmacokinetics; Oligonucleotides - pharmacology; Oligonucleotides, Antisense - administration & dosage; Oligonucleotides, Antisense - pharmacokinetics; Oligonucleotides, Antisense - pharmacology; Pharmacokinetics; Pharmacology; Plasma; Protein Binding; Risk factors; RNA, Messenger - metabolism; Safety; Studies; Treatment Outcome; Young Adult